News

European Fellowship Scheme for Researchers at Risk – Introduction of the call, policy & application information

Published on | 2 years ago

Programmes
MSCA Horizon Europe

A call for a pilot European Fellowship Scheme for Researchers at Risk is currently open with deadline 7 September 2023. The indicative call budget is €6 million to fund one project. The main objective of the call is:

  • to pilot a European fellowship scheme to support researchers at risk to address the currently fragmented and limited support at EU level for researchers at risk.
  • to enhance the support for researchers at risk to continue their work in a safe environment.
  • to set up, test and validate selection procedures for at-risk researchers and matchmaking with hosts in the EU (approximately 30 fellowships for non-EU researchers with different legal statuses).

The European Fellowship Scheme for Researchers at Risk action was allocated to the Directorate-General for Education, Youth, Sport and Culture (DG EAC) and the implementation will be monitored by the European Research Executive Agency (REA). Please find in these two videos more information on the background and application procedure for this call.

  • Introduction & policy by Marija Mitic, Policy analyst, DG EAC video
  • Call conditions, application documents & award criteria by Andrea Hutterer, Call coordinator, REA video

Any questions on the call can be send to REA-MSCA-HE-RR@ec.europa.eu

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1822 articles available search in articles 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.